CCL21 and neoplasm: Additionally, anti-PD-1 treatment of NSCLC in an immunocompetent mouse model revealed that circulating TFH cells are associated with enhanced B-cell activation capacity, increased CCL21 levels, increased number of TLSs in tumors, and the production of antitumor antibodies in situ that interfere with tumor growth (147).